Abstract:Antineoplastic resistance represents a multifaceted challenge for cancer therapy and diagnostics. Extensive molecular heterogeneity, even within neoplasms of the same type, can elicit distinct outcomes of administering therapeutic pressures, frequently leading to the development of drug-resistant populations. Improved success of oncotherapies merits the exploration of precise molecular imaging technologies that can detect not only anatomical but also molecular changes in tumors and their microenvironment, early on in the treatment regimen. To this end, we developed magnetic resonance molecular imaging (MRMI) strategies to target the extracellular matrix oncoprotein, extradomain-B fibronectin (EDB-FN), for non-invasive assessment and therapeutic monitoring of drug-resistant colorectal cancer (CRC). Methods: Two drug-resistant CRC lines generated from parent DLD-1 and RKO cells by long-term treatment with 5'-FU and 5'-FU plus CB-839 respectively, were characterized for functional and gene expression changes using 3D culture, transwell invasion, qRT-PCR, and western blot assays. Contrast-enhanced MRMI of EDB-FN was performed in athymic nu/nu mice bearing subcutaneous tumor xenografts with 40 µmol/kg dose of macrocyclic ZD2-targeted contrast agent MT218 [ZD2-N3-Gd (HP-DO3A)] on a 3T MRS 3000 scanner. Immunohistochemistry was conducted on patient specimens and xenografts using anti-EDB-FN antibody G4. Results: Analyses of TCGA and GTEx databases revealed poor prognosis of colon cancer patients with higher levels of EDB-FN. Similarly, immunohistochemical staining of patient specimens showed increased EDB-FN expression in primary colon adenocarcinoma and hepatic metastases, but none in normal adjacent tissues. Drug-resistant DLD1-DR and RKO-DR cells were also found to demonstrate enhanced invasive potential and significantly elevated EDB-FN expression over their parent counterparts. MRMI of EDB-FN with 40 µmol/kg dose of MT218 (60% lower than the clinical dose) resulted in robust signal enhancement in the drug-resistant CRC xenografts with 84-120% increase in their contrast-to-noise ratios (CNRs) over the non-resistant counterparts. The feasibility of non-invasive therapeutic monitoring using MRMI of EDB-FN was also evaluated in drug-resistant DLD1-DR tumors treated with a pan-AKT inhibitor MK2206-HCl. The treated drug-resistant tumors failed to respond to therapy, which was accurately detected by MRMI with MT218, demonstrating higher signal enhancement and increased CNRs in the 4-week follow-up scans over the pre-treatment scans. Conclusions: EDB-FN is a promising molecular marker for assessing drug resistance. MRMI of EDB-FN with MT218 at a significantly reduced dose can facilitate effective non-invasive assessment and treatment response monitoring of drug-resistant CRC, highlighting its translational potential for active surveillance and management of CRC and other malignancies.

Application of the Improved MTT Assay in Predicting the Intrinsic Drug Resistance of Liver Cancer

Drug Susceptibility Test in Carcinoma of Gallbladder and Cholangiocarcinoma

Reversal in Multidrug Resistance by Magnetic Nanoparticle of Fe3o4 Loaded with Adriamycin and Tetrandrine in K562/A02 Leukemic Cells

[The Effect of MDR1 (P-Gp) and ABCG2 on the Drug Resistance in Hep 2 Cells].

Evaluation of the in Vitro Chemosensitivity and Correlation with Clinical Outcomes in Lung Cancer Using the ATP-TCA.

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer

Association Between Mismatch Repair Gene and Irinotecan-Based Chemotherapy in Metastatic Colon Cancer

PREDICTION OF SENSITIVITY ON HEPATOMA CHEMOIMMUNOTHERAPY USING MTT ASSAY

Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer

Analysis on the Detected Chemotherapeutic Drug Sensitivity Results of Gastric Cancer Cells by Using MTT Method

[Antitumor Effects of Chemotherapeutic Drugs on Fresh Human Gastric Cancer Cells and Their Relationships to Expressions of P-glycoprotein and Glutathione S Transferase-Pi].

Effects of Multidrug Resistance Reversing Agent on P-glycoprotein,EMMPRIN and MMP Expression in Human Breast Cancer Cells

Single Photon Emission Computed Tomography Imaging Using 99Tcm-Methoxyisobuty-lisonitrile Predict the Multi-Drug Resistance and Chemotherapy Efficacy of Lung Cancer

Human Drug Efflux Transporter ABCC5&nbsp;Confers Sensitivity and Acquired Resistance to Pemetrexed in Breast Cancer

Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer

Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin

Predicting Drug Sensitivity and Resistance

Effect of Multidrug-Resistant-proteins in Neoadjuvant Chemotherapy in Patients with Breast Cancer

Dynamic Quantitative Detection of ABC Transporter Family Promoter Methylation by MS-HRM for Predicting MDR in Pancreatic Cancer.

Synthesis and Biological Evaluation of Novel Podophyllotoxin-Nsaids Conjugates As Multifunctional Anti-Mdr Agents Against Resistant Human Hepatocellular Carcinoma Bel-7402/5-FU Cells

Expression of Multi-Drug Resistance-Related Genes MDR3 and MRP As Prognostic Factors in Clinical Liver Cancer Patients.